Delisting risk
VYNE Therapeutics (VYNE)
Develops BET inhibitor therapies for inflammatory and immune-mediated diseases.
$28.56
At close0.00 (0.00%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions42 holders · as of Mar 31, 2026 | ≥ 9.86% | 263.2K shares | |
| Strategic holders1 holder · as of Jul 30, 2026 | 9.97% | 266.3K shares | |
| Otherremainder | ≤ 80.17% | 2.14M shares |
2.67M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (2.67M in the company's Sep 3, 2026 report, 667.7K elsewhere); stakes use the report.
Institutional filings for YARW (100% of the company) are not on file here, so the institutional figure is a floor.
Institutions13F, as of Mar 31, 2026
42 holders · 13.16M shares · 9 new positions · 19 increased · 5 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 2.00M | 74.91% | +1.00M | May 15, 2026 |
| LYNX1 Capital Management LP | 1.63M | 61.01% | +1.63Mnew | May 4, 2026 |
| Shay Capital LLC | 1.61M | 60.31% | −14.1K | May 15, 2026 |
| Anson Funds Management LP | 1.24M | 46.56% | −31.3K | May 19, 2026 |
| Adar1 Capital Management, LLC | 1.06M | 39.85% | +810.1K | May 18, 2026 |
| T3 Companies, LLC | 945.0K | 35.40% | 0 | May 7, 2026 |
| Braidwell LP | 916.1K | 34.31% | +916.1Knew | May 15, 2026 |
| Citadel Advisors LLC | 514.4K | 19.27% | +483.9K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 6.00% | 13G | May 15, 2026 ↗ | |
| Zhang Xiaofan | 5.60% | 13G | Jun 15, 2026 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.